DacomitinibMeSH Supplementary Concept

https://www.has-sante.fr/jcms/p_3119789/fr/vizimpro
2019
false
false
false
France
dacomitinib
administration, oral
treatment outcome
antineoplastic agents
protein kinase inhibitors
insurance, health, reimbursement
adult
neoplasm metastasis
carcinoma, non-small-cell lung
carcinoma, non-small-cell lung
Product containing precisely dacomitinib 45 milligram/1 each conventional release oral tablet (clinical drug)
Product containing precisely dacomitinib 30 milligram/1 each conventional release oral tablet (clinical drug)
Product containing precisely dacomitinib 15 milligram/1 each conventional release oral tablet (clinical drug)
evaluation of the transparency committee
dacomitinib
quinazolinones

---
https://www.ema.europa.eu/en/medicines/human/EPAR/vizimpro
2019
false
false
false
United Kingdom
French
English
treatment outcome
syndication feed
summary of product characteristics
package leaflet
drug evaluation
drug approval
europe
dacomitinib
antineoplastic agents
antineoplastic agents
adult
carcinoma, non-small-cell lung
neoplasm metastasis
Advanced Malignant Neoplasm
ErbB Receptors
carcinoma, non-small-cell lung
administration, oral
product surveillance, postmarketing
protein kinase inhibitors
protein kinase inhibitors
aged
drug interactions
pregnancy
breast feeding
EGFR protein, human
Progression-Free Survival
drug evaluation, preclinical
Product containing precisely dacomitinib 15 milligram/1 each conventional release oral tablet (clinical drug)
Product containing precisely dacomitinib 30 milligram/1 each conventional release oral tablet (clinical drug)
Product containing precisely dacomitinib 45 milligram/1 each conventional release oral tablet (clinical drug)
Tyrosine Kinase Inhibitors
dacomitinib
dacomitinib
ErbB Receptors
quinazolinones
quinazolinones

---